Research Analysts Issue Forecasts for Agenus Q2 Earnings

Agenus Inc. (NASDAQ:AGEN) – Analysts at HC Wainwright dropped their Q2 2026 earnings estimates for Agenus in a report released on Monday, July 13th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.06. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Agenus’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Agenus’ FY2026 earnings at $0.83 EPS, FY2027 earnings at ($0.16) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.26) EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.

Agenus Stock Performance

AGEN stock opened at $5.08 on Wednesday. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $8.70. The company has a market capitalization of $211.53 million, a price-to-earnings ratio of 3.19 and a beta of 1.55. The business’s 50 day moving average price is $3.37 and its two-hundred day moving average price is $3.45.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing the consensus estimate of $2.10 by ($1.08). The company had revenue of $33.74 million during the quarter, compared to analysts’ expectations of $129.50 million. Agenus had a negative return on equity of 31.66% and a net margin of 50.49%.

Institutional Investors Weigh In On Agenus

Institutional investors have recently modified their holdings of the stock. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 4th quarter worth about $31,000. R Squared Ltd bought a new stake in Agenus during the 4th quarter valued at about $41,000. Redwood Family Wealth LLC bought a new stake in Agenus during the 4th quarter valued at about $44,000. Quadrature Capital Ltd purchased a new position in Agenus in the fourth quarter worth about $54,000. Finally, Squarepoint Ops LLC purchased a new position in Agenus in the third quarter worth about $54,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Agenus

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Agenus secured an oversubscribed private placement worth up to $340 million, with about $85 million upfront and additional capital available through warrant exercises. Investors are reacting to the stronger balance sheet and the extended cash runway, which could fund the company’s lead Phase 3 ROBBIN colon cancer study. Agenus in Up to $340 Million Private Placement to Advance Trial
• Positive Sentiment: The company also narrowed its development strategy, discontinuing support for the BATTMAN metastatic colorectal study and concentrating resources on BOT+BAL in MSS colon cancer. That strategic pivot is being viewed as a clearer path to value creation and a key reason for the stock’s recent surge. Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer
• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target to $30, while boosting its FY2026 and several out-year EPS estimates. Even though the firm trimmed some near-term quarterly estimates, the higher full-year outlook and maintained bullish stance may be reinforcing investor optimism. HC Wainwright analyst update
• Neutral Sentiment: HC Wainwright lowered some quarterly and later-year EPS forecasts, including Q2 2026 and FY2029/FY2030, reflecting continued uncertainty around Agenus’ longer-term profitability. These revisions are mixed and may temper some enthusiasm. HC Wainwright estimate revisions
• Negative Sentiment: Recent commentary also points to profit-taking after the sharp rally, suggesting some traders are locking in gains following the stock’s big run-up. Why Is Agenus Stock Falling on Tuesday?

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.